CL2022000050A1 - Formas polimórficas de (r)-4- (1-((3- (difluorometil)-1-metil-1h-pirazol-4-il)sulfonil) -1-fluoroetil)-n-(isoxazol-3-il)piperidina -1-carboxamida - Google Patents

Formas polimórficas de (r)-4- (1-((3- (difluorometil)-1-metil-1h-pirazol-4-il)sulfonil) -1-fluoroetil)-n-(isoxazol-3-il)piperidina -1-carboxamida

Info

Publication number
CL2022000050A1
CL2022000050A1 CL2022000050A CL2022000050A CL2022000050A1 CL 2022000050 A1 CL2022000050 A1 CL 2022000050A1 CL 2022000050 A CL2022000050 A CL 2022000050A CL 2022000050 A CL2022000050 A CL 2022000050A CL 2022000050 A1 CL2022000050 A1 CL 2022000050A1
Authority
CL
Chile
Prior art keywords
fluoroethyl
difluoromethyl
pyrazol
carboxamide
piperidine
Prior art date
Application number
CL2022000050A
Other languages
English (en)
Spanish (es)
Inventor
Zhong Min
Monnier Olivier
JELIN Jean-Philippe
DUVOUX Richard
Alie Jean
Ochsenbein Philippe
Original Assignee
Myokardia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myokardia Inc filed Critical Myokardia Inc
Publication of CL2022000050A1 publication Critical patent/CL2022000050A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2022000050A 2019-07-16 2022-01-10 Formas polimórficas de (r)-4- (1-((3- (difluorometil)-1-metil-1h-pirazol-4-il)sulfonil) -1-fluoroetil)-n-(isoxazol-3-il)piperidina -1-carboxamida CL2022000050A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962874855P 2019-07-16 2019-07-16

Publications (1)

Publication Number Publication Date
CL2022000050A1 true CL2022000050A1 (es) 2022-10-14

Family

ID=71895284

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022000050A CL2022000050A1 (es) 2019-07-16 2022-01-10 Formas polimórficas de (r)-4- (1-((3- (difluorometil)-1-metil-1h-pirazol-4-il)sulfonil) -1-fluoroetil)-n-(isoxazol-3-il)piperidina -1-carboxamida

Country Status (14)

Country Link
US (2) US20210053939A1 (OSRAM)
EP (1) EP3999504A1 (OSRAM)
JP (2) JP2022540678A (OSRAM)
KR (1) KR20220035176A (OSRAM)
CN (1) CN114127061A (OSRAM)
AU (1) AU2020315605A1 (OSRAM)
BR (1) BR112022000474A2 (OSRAM)
CA (1) CA3143965A1 (OSRAM)
CL (1) CL2022000050A1 (OSRAM)
CO (1) CO2022000117A2 (OSRAM)
IL (1) IL289817A (OSRAM)
MX (1) MX2022000606A (OSRAM)
PE (1) PE20220645A1 (OSRAM)
WO (1) WO2021011586A1 (OSRAM)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116082326B (zh) * 2022-12-16 2024-12-27 药康众拓(江苏)医药科技有限公司北京分公司 一种氘代吡唑磺酰甲基-哌啶异噁唑脲类化合物及其用途
CN117865941B (zh) * 2024-03-13 2024-06-28 上海方予健康医药科技有限公司 取代哌啶化合物及其制备方法和应用
WO2025244956A1 (en) 2024-05-20 2025-11-27 MyoKardia, Inc. Methods of manufacturing danicamtiv

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6358980B1 (en) 1999-01-27 2002-03-19 American Cyanamid Company Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
WO2005117882A2 (en) 2004-04-20 2005-12-15 Incyte Corporation Hydroxamic acid derivatives as metalloprotease inhibitors
BRPI0512193B8 (pt) 2004-06-17 2021-05-25 Cytokinetics Inc composto ou sal farmaceuticamente aceitável, composição farmacêutica, e, uso do composto ou sal
EP1836179B1 (en) 2004-12-30 2015-05-06 Janssen Pharmaceutica NV Piperidine- and piperazine-1-carboxylic acid amide derivatives and related compounds as modulators of fatty acid amide hydrolase (faah) for the treatment of anxiety, pain and other conditions
CN101133026B (zh) 2005-03-03 2011-07-06 霍夫曼-拉罗奇有限公司 作为治疗Ⅱ型糖尿病用的11β-羟基类固醇脱氢酶抑制剂的1-磺酰基-哌啶-3-羧酸酰胺衍生物
WO2008120759A1 (ja) 2007-03-30 2008-10-09 Japan Tobacco Inc. ウレア化合物およびその用途
WO2008156142A1 (ja) 2007-06-20 2008-12-24 Mitsubishi Tanabe Pharma Corporation 新規なマロン酸スルホンアミド誘導体およびその医薬用途
US20090069288A1 (en) 2007-07-16 2009-03-12 Breinlinger Eric C Novel therapeutic compounds
CA2697551C (en) 2007-09-20 2013-03-12 Irm Llc Piperidine derivatives as modulators of gpr119 activity
MX2010003621A (es) 2007-10-01 2010-04-14 Hoffmann La Roche N-heterociclil biaril carboxamidas como antagonistas del receptor ccr.
CA2701932C (en) 2007-10-09 2015-10-20 F. Hoffmann-La Roche Ag Chiral cis-imidazolines
JO3465B1 (ar) 2008-06-19 2020-07-05 Takeda Pharmaceuticals Co مركب متغاير الحلقه واستخدامه
US8324178B2 (en) 2008-10-31 2012-12-04 The Regents Of The University Of California Method of treatment using alpha-1-adrenergic agonist compounds
JP5329646B2 (ja) 2009-04-01 2013-10-30 パナソニック株式会社 デジタル周波数/位相ロックドループ
WO2011059021A1 (ja) 2009-11-11 2011-05-19 大日本住友製薬株式会社 8-アザビシクロ[3.2.1]オクタン-8-カルボキサミド誘導体
WO2015005305A1 (ja) 2013-07-09 2015-01-15 小野薬品工業株式会社 Alxr作動化合物
HUE037134T2 (hu) 2013-08-07 2018-08-28 Merck Patent Gmbh Piperidin-karbamid-származékok
AU2015209239C1 (en) 2014-01-24 2026-05-07 Turning Point Therapeutics, Inc. Diaryl macrocycles as modulators of protein kinases
PH12021553074A1 (en) 2015-01-22 2023-03-06 Myokardia Inc 4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (dcm)
CA3138080A1 (en) 2019-05-19 2020-11-26 Jean-Francois TAMBY Treatment of systolic dysfunction and heart failure with reduced ejection fraction with the compound(r)-4-(1-((3-(difluoromethyl)-1-methyl-1h-pyrazol-4-yl)sulfonyl)-1-fluoroethyl) n-(isoxazol-3-yl)piperidine-1-carboxamid

Also Published As

Publication number Publication date
US20220289709A1 (en) 2022-09-15
PE20220645A1 (es) 2022-04-28
CN114127061A (zh) 2022-03-01
KR20220035176A (ko) 2022-03-21
WO2021011586A1 (en) 2021-01-21
JP2022540678A (ja) 2022-09-16
MX2022000606A (es) 2022-03-11
JP2025148397A (ja) 2025-10-07
TW202116765A (zh) 2021-05-01
IL289817A (en) 2022-03-01
BR112022000474A2 (pt) 2022-05-17
US12459919B2 (en) 2025-11-04
US20210053939A1 (en) 2021-02-25
AU2020315605A1 (en) 2022-03-03
EP3999504A1 (en) 2022-05-25
CO2022000117A2 (es) 2022-01-17
CA3143965A1 (en) 2021-01-21

Similar Documents

Publication Publication Date Title
DOP2022000172A (es) Compuestos de piperidina urea 4-metilsulfonil-sustituidos para el tratamiento de miocardiopatía dilatada (mcd)
CO2022000117A2 (es) Formas polimórficas de (r)-4- (1-((3- (difluorometil)-1-metil-1h-pirazol-4-il)sulfonil) -1-fluoroetil)-n-(isoxazol-3-il)piperidina -1-carboxamida
CO2021015505A2 (es) Tratamiento de la disfunción sistólica e insuficiencia cardíaca con fracción de eyección reducida con el compuesto (r) -4-(1-((3-(difluorometil) -1-metil-1h-pirazol-4-il) sulfonil) -1-fluoroetil) -n-(isoxazol-3-il) piperidin-1-carboxamida
CR20160032A (es) Compuestos de pirimidinodiona contra estados cardíacos
CL2020000427A1 (es) Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos.
IL286465A (en) Electrode configurations for diagnosis of arrhythmlas
CO2021005540A2 (es) Compuestos de pirimidinodiona bicíclicos sustituidos con tetrahidropirano (thp)
BR112022000494A2 (pt) Polimorfo, métodos para preparar polimorfo, para tratar doença cardíaca, para tratar uma doença ou condição e para inibir o sarcômero cardíaco, e, composição farmacêutica
UY38160A (es) Partículas implantables y métodos relacionados
CO2019000471A2 (es) Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de ácido lisofosfatídico (lpa)
CU20120015A7 (es) Piridina y pirazina como derivados de moduladores de la proteína kinasa
PE20200924A1 (es) Compuestos de bisamida sustituida que activan el sarcomero cardiaco
MX342409B (es) Tratamiento de enfermedades cardiacas.
MX378565B (es) Derivados de indazol como antagonistas de integrina alfa v.
ECSP19001018A (es) Moduladores del receptor adrenérgico beta -3 útiles para el tratamiento o prevención de trastornos relacionados con los mismos
BR112017019952A2 (pt) sutura de malha com características antienrolamento
MX2016013801A (es) Moduladores del receptor acoplado a la proteina g 40 (gpr40) de pirrolidina para el tratamiento de enfermedades como la diabetes.
PH12018502378B1 (en) Benzenesulfonamide compounds and their use as therapeutic agents
MX2021014654A (es) Implante de mama biologico.
MX2023012758A (es) Composiciones y metodos para el tratamiento de la enfermedad ocular asociada con angiogenesis.
HUE058867T2 (hu) Javított vegyület szívelégtelenség kezelésére
IL277141A (en) Compounds for the treatment of heart rhythm disturbances and heart failure
MX2022005914A (es) Compuestos novedosos para el diagnostico, tratamiento y prevencion de enfermedades asociadas con la agregacion de alfa-sinucleina.
CO2024017046A2 (es) Composiciones y métodos para tratar una enfermedad cardíaca
Slatinski et al. Diagnostic challenges in treating patient with cardiogenic shock caused by Lyme disease